COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
- Date 8 Feb 2021
The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose.
Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with protection maintained to the second dose. With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82% (CI: 63%, 92%).
The analysis also showed the potential for the vaccine to reduce asymptomatic transmission of the virus, based on weekly swabs obtained from volunteers in the UK trial. The data showed that PCR positive readings were reduced by 67% (CI: 49%, 78%) after a single dose, and 50% (CI: 38% to 59%) after the two dose regimen, supporting a substantial impact on transmission of the virus.
The primary analysis for efficacy was based on 17,177 participants accruing 332 symptomatic cases from the Phase III UK (COV002), Brazil (COV003) and South Africa (COV005) trials led by Oxford University and AstraZeneca, a further 201 cases than previously reported.
Sir Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, said: “This primary analysis reconfirms that our vaccine prevents severe disease and keeps people out of hospital. In addition, extending the dosing interval not only boosts the vaccine’s efficacy, but also enables more people to be vaccinated upfront. Together with the new findings on reduced transmission, we believe this vaccine will have a real impact on the pandemic.”
You might also be interested in these articles
Steaming up Success: ARU student’s path from café to creativity
We recently did a Q&A session with Anglia Ruskin student Soorya Jith, who started his journey as a Barista at the Lakeside Café within the Bradfield Centre on Cambridge Science Park. He has now transitioned to Krank, also located on the Park, as a Junior Graphic Designer.
Sun 21 Apr 2024
Cambridge Science Park
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
Xampla welcomes former P&G chemist to team as scale-up accelerates
accelerates CREATOR of plastic-free, natural materials, Xampla, continues to scale-up the commercialisation of its biodegradable Morro materials with new industry hire.
Fri 1 Mar 2024
Xampla Ltd
